glp-1 agonist pharmacology Frontiers GLP-1 Receptor Agonists as Treatments
Description
10 This means that semaglutide (GLP-1 RA) drugs are not silver bullets for sustained weight loss
HJG is consultant and member of the Global Obesity Advisory Board of Novo Nordisk
There are now 8 approved medications in this class, including the newest tirzepatide which also acts on the GIP receptors
doi: 10.1016/j.beem.2009.03.001
The study will enroll 46 participants (approximately 23 per arm) to assess semaglutides effects on cuereactivity as well as its preliminary efficacy, safety, and tolerability as an adjunct treatment for opioid recovery.
